Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Brooks

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Health and Quality of Life Outcomes|November 2, 2015
A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary diseaseMaggie Tabberer, Jean Brooks, Teresa Wilcox
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Mapping the COPD Assessment Test onto EQ-5DChristopher K Hoyle, Margaret Tabberer, Jean Brooks
Clinical Drug Investigation|September 3, 2015
Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup AnalysesAhmar Iqbal, Neil C Barnes, Jean Brooks
BMC Pulmonary Medicine|January 8, 2014
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over studyAlison Church, Misba Beerahee, Jean Brooks, et al.
Pulmonary Pharmacology & Therapeutics|September 8, 2012
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialGregory Feldman, Robert R Walker, Jean Brooks, et al.
COPD|October 10, 2015
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind StudiesThomas M Siler, Edward Kerwin, Karen Singletary, et al.
Respiratory Research|July 13, 2014
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyJames F Donohue, Dennis Niewoehner, Jean Brooks, et al.
Respiratory Medicine|April 14, 2012
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDJames F Donohue, Antonio Anzueto, Jean Brooks, et al.
Respiratory Physiology & Neurobiology|October 3, 2012
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsMarc Decramer, François Maltais, Gregory Feldman, et al.
Respiratory Medicine|April 26, 2016
Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary diseaseLynn Condreay, Lingkang Huang, Elizabeth Harris, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Health and Quality of Life Outcomes|November 2, 2015
A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary diseaseMaggie Tabberer, Jean Brooks, Teresa Wilcox
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Mapping the COPD Assessment Test onto EQ-5DChristopher K Hoyle, Margaret Tabberer, Jean Brooks
Clinical Drug Investigation|September 3, 2015
Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup AnalysesAhmar Iqbal, Neil C Barnes, Jean Brooks
BMC Pulmonary Medicine|January 8, 2014
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over studyAlison Church, Misba Beerahee, Jean Brooks, et al.
Pulmonary Pharmacology & Therapeutics|September 8, 2012
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialGregory Feldman, Robert R Walker, Jean Brooks, et al.
COPD|October 10, 2015
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind StudiesThomas M Siler, Edward Kerwin, Karen Singletary, et al.
Respiratory Research|July 13, 2014
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyJames F Donohue, Dennis Niewoehner, Jean Brooks, et al.
Respiratory Medicine|April 14, 2012
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDJames F Donohue, Antonio Anzueto, Jean Brooks, et al.
Respiratory Physiology & Neurobiology|October 3, 2012
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsMarc Decramer, François Maltais, Gregory Feldman, et al.
Respiratory Medicine|April 26, 2016
Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary diseaseLynn Condreay, Lingkang Huang, Elizabeth Harris, et al.
Pageof 2